What To Expect From Spero Therapeutics Inc (SPRO) Q3 2024 …

Nov 13, 2024 · Spero Therapeutics Inc (NASDAQ:SPRO) is set to release its Q3 2024 earnings on Nov 14, 2024. The consensus estimate for Q3 2024 revenue is $7.67 million, and the …

CouponFollow Extension

$7.67
OFF

What To Expect From Spero Therapeutics Inc (SPRO) Q3 2024 …

6 days from now

Nov 13, 2024 · Spero Therapeutics Inc (NASDAQ:SPRO) is set to release its Q3 2024 earnings on Nov 14, 2024. The consensus estimate for Q3 2024 revenue is $7.67 million, and the …

yahoo.com

22%
OFF

What To Expect From Spero Therapeutics Inc (SPRO) Q3 2024 …

6 days from now

After releasing the results, Spero Therapeutics Inc (SPRO) was down by -5.22% in one day. Spero Therapeutics Inc (SPRO, Financial) 12 Month Price Targets. Based on the one-year …

gurufocus.com

52%
OFF

Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue …

6 days from now

Nov 14, 2024 · Spero Therapeutics (SPRO) delivered earnings and revenue surprises of -18.52% and 41.44%, respectively, for the quarter ended September 2024. Do the numbers hold clues …

zacks.com

FAQs about What To Expect From Spero Therapeutics Inc (SPRO) Q3 2024 … Coupon?

When will Spero Therapeutics Inc (Spro) release its Q3 2024 earnings?

Spero Therapeutics Inc (NASDAQ:SPRO) is set to release its Q3 2024 earnings on Nov 14, 2024. The consensus estimate for Q3 2024 revenue is $7.67 million, and the earnings are expected to come in at -$0.36 per share. The full year 2024's revenue is expected to be $30.05 million, and the earnings are expected to be -$1.13 per share. ...

What is the target price for Spero Therapeutics Inc (Spro)?

After releasing the results, Spero Therapeutics Inc (NASDAQ:SPRO) was down by -5.22% in one day. Based on the one-year price targets offered by 2 analysts, the average target price for Spero Therapeutics Inc (NASDAQ:SPRO) is $5 with a high estimate of $5 and a low estimate of $5. ...

How did Spero Therapeutics Inc's (Spro) earnings compare to analysts' expectations?

In the previous quarter of June 30, 2024, Spero Therapeutics Inc's (NASDAQ:SPRO) actual revenue was $10.2 million, which beat analysts' revenue expectations of $3.27 million by 212.12%. Spero Therapeutics Inc's (NASDAQ:SPRO) actual earnings were -$0.33 per share, which beat analysts' earnings expectations of -$0.38 per share by 13.16%. ...

How did Spero Therapeutics Inc (Spro) perform in one day?

Spero Therapeutics Inc's (NASDAQ:SPRO) actual earnings were -$0.33 per share, which beat analysts' earnings expectations of -$0.38 per share by 13.16%. After releasing the results, Spero Therapeutics Inc (NASDAQ:SPRO) was down by -5.22% in one day. ...

Should you buy Spero Therapeutics (Spro) stock?

Currently, the analyst consensus on Spero Therapeutics is a Moderate Buy with an average price target of $5.00. SPRO market cap is currently $64.33M and has a P/E ratio of 14.86. Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is negative on the stock. ...

How did Spero perform in the third quarter of 2024?

The company reported a net loss of $17.1 million for the third quarter of 2024, reflecting increased research and development expenses as it shifts focus to other strategic projects. Financially, Spero recorded total revenues of $13.5 million for the third quarter, driven by grant and collaboration revenues. ...